Business Expansions, New Contracts, Product Launches, and Regulatory Approvals - Research Report on Alexion, Actavis, CombiMatrix, Globus Medical, and Teleflex PR Newswire NEW YORK, June 28, 2013 NEW YORK, June 28, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Wall Street Reports announced new research reports highlighting Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Actavis Inc. (NYSE: ACT), CombiMatrix Corporation (NASDAQ: CBMX), Globus Medical Inc. (NYSE: GMED), and Teleflex Incorporated (NYSE: TFX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Alexion Pharmaceuticals, Inc. Research Report On June 17, 2013, Alexion Pharmaceuticals Inc. (Alexion) reported that it was joined by state and local officials in a ceremony for 100 College Street, a laboratory office building that will house the Company's new global headquarters in New Haven, Connecticut. According to Alexion, the event marked a milestone in the expansion of its research and business operations as it continues to develop a broad portfolio of life-transforming therapies for patients. Leonard Bell, MD, Chief Executive Officer of Alexion, said, "Our new global headquarters will support our continued growth as we work to develop and deliver life-transforming therapies for patients with severe and life-threatening disorders that are also ultra-rare." Alexion reported that it will be the anchor tenant in 100 College Street, occupying nine floors, and expects the building to be open for occupancy in 2015. The Full Research Report on Alexion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/451f_ALXN] Actavis Inc. Research Report On June 25, 2013, Actavis Inc. (Actavis) announced that Health Canada has approved the Company's application to market FIBRISTAL (ulipristal acetate) for the treatment of moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age, who are eligible for surgery. Expected to be available in Canada in Q3 2013, Actavis claims that FIBRISTAL is a breakthrough first-in-class oral treatment that offers an important new option for women in Canada with uterine fibroids, being the first approved medication to reduce fibroid size as well as control symptoms. Current treatments for uterine fibroids include off-label medication to reduce symptoms, or surgery to remove fibroids if they become severe. The Company stated that two double-blind, controlled, multicenter, Phase 3 studies showed that FIBRISTAL significantly reduced heavy bleeding during menstruation, pain and discomfort and the overall volume of fibroids. Besides, the Company claims that a three month treatment with FIBRISTAL helps to maintain the reduced size of fibroid for at least six months. The Full Research Report on Actavis Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/4b90_ACT] CombiMatrix Corporation Research Report On June 25, 2013, CombiMatrix Corporation (CombiMatrix) announced that its chromosomal microarray analysis (CMA) test for miscarriage analysis has received conditional approval from the New York State's Department of Health for testing on patient samples from the state. The CMA test for miscarriage analysis, also called Product of Conception test, is currently the Company's fastest growing test in terms of volumes. On June 18, 2013, the Company had announced that volumes from both of its prenatal CMA tests have increased significantly in the past six months following the publication of data from two National Institutes of Health (NIH) studies that indicated the superiority of CMA over traditional karyotyping for identifying clinically significant genetic abnormalities. Mark McDonough, CEO of CombiMatrix, said, "As approved under the conditional license, we will now begin to sell directly to customers and to seek distribution partnerships to leverage our internal sales force." The Full Research Report on CombiMatrix Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/75e0_CBMX] Globus Medical Inc. Research Report On June 20, 2013, Globus Medical Inc. (Globus) announced the launch of LATIS, a minimally invasive (MIS) lumbar interbody fusion spacer for patients suffering from degenerative disc disease (DDD). According to the Company, the implant may be inserted through an MIS transforaminal lumbar interbody fusion (TLIF) approach and expands laterally to provide a footprint and graft volume equivalent to an anterior lumbar interbody fusion (ALIF) spacer or lateral lumbar interbody fusion (LLIF) spacer. Andrew Iott, Senior Vice President, Global Product Development of Globus, said, "This new addition to our MIS portfolio is the first expandable implant on the market to offer the benefits of a traditional anterior implant, without the two-part disruptive surgical procedure. Combined with posterior stabilization using our REVOLVE MIS pedicle screw system, the entire procedure is designed and intended to maximize preservation of the stabilizing muscles of the lower back." Full Research Report on Globus Medical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/5f95_GMED] Teleflex Incorporated Research Report On June 25, 2013, Teleflex Incorporated (Teleflex) announced that it has signed a new agreement with HealthTrust for its complete line of LMA Laryngeal Masks. Under the term of the agreement, Teleflex will provide HealthTrust's 1,400 member hospital access to its comprehensive portfolio of laryngeal masks, with effect from July 1, 2013.. The Company informed that the full offering provides airway management products including LMA Supreme Laryngeal Mask, the LMA Classic Airway, the LMA Unique Airway, and the LMA ProSeal Airway. Cary Vance, President, Anesthesia & Respiratory Division of Teleflex, said, "This new agreement with HealthTrust further strengthens Teleflex's position as a market leader in laryngeal masks in the United States." The Full Research Report on Teleflex Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/9f7f_TFX] EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE Wall Street Reports Contact: Media Contact: WSReports.com, Phone #: +1-310-496-8071 (North America)
Business Expansions, New Contracts, Product Launches, and Regulatory Approvals - Research Report on Alexion, Actavis,
Press spacebar to pause and continue. Press esc to stop.